Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis

NCT02595970 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Secukinumab

Sponsor

Novartis Pharmaceuticals